Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson
Executive Summary
The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.
You may also be interested in...
Medicare ‘Maximum Fair Price’ And The Importance Of Choosing The Right Therapeutic Alternatives
Biopharma industry raises alarm that Medicare might identify therapeutic comparators for drugs selected for price negotiation based mainly on costs.
CMS Building Rx Price Negotiating Staff Internally; Contracting With Outside Groups ‘Not On Radar’
CMS head Brooks-LaSure says agency is making progress in staffing the drug pricing control programs established by the Inflation Reduction Act. Medicare Center deputy director Cheri Rice will be its acting director under just-unveiled management structure.
Medicare Price ‘Negotiation’ Process Could Enable National Value Framework – CMS’ Blum
Centers for Medicare and Medicaid Services chief operating officer Jonathan Blum discusses implementation of an unprecedented new price setting program and how it might impact value-based pricing more broadly in a recent interview with Health Affairs.